Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reduced-Dose IMRT With or Without Cisplatin in p16+ Oropharyngeal Cancer
NCT02254278Phase 2Completed
- Sponsor
- NRG Oncology
- Start
- Oct 2014
- Primary completion
- Jun 2019
- Modality
- Nanoparticles, Small Molecules
- Countries
- 4
01
Overview
A Phase 2 trial of Cisplatin micelle injection (HA132) in oropharyngeal squamous cell carcinoma (OPSCC), sponsored by NRG Oncology. Started Oct 2014; status: completed.
02
Drugs
Cisplatin micelle injection (HA132)
03
Conditions
oropharyngeal squamous cell carcinoma (OPSCC)
Beyond the preview
Go deeper on NCT02254278.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02254278.